Status:

UNKNOWN

Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients

Lead Sponsor:

Armando Santoro, MD

Conditions:

Hodgkin's Lymphoma

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Test of bendamustine in combination with gemcitabine and vinorelbine could contribute to a higher response rate with the reduction of toxic side effects

Detailed Description

The aim of this study is to evaluate bendamustine, gemcitabine and vinorelbine (BeGEV) scheme efficacy as induction therapy to high dose chemotherapy with Allogeneic Hematopoietic Stem-Cell Transplant...

Eligibility Criteria

Inclusion

  • relapsed/refractory disease after receiving one line of standard chemotherapy
  • history of classical Hodgkin's Lymphoma (HL)
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
  • at least one site of measurable nodal disease at baseline ≥ 1.5 cm
  • Absolute Neutrophils Count (ANC) ≥ 1.5 x 109/L; Platelets count ≥ 75 x 109/L

Exclusion

  • Diagnosis of Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL)
  • prior radiation therapy ≤ 3 weeks prior to start of study treatment
  • any concurrent anti-cancer therapy
  • evidence of another malignancy not in remission or history of such a malignancy within the last 2 years.
  • aspartate aminotransferase (AST/SGOT) and/or alanine aminotransferase (ALT/SGPT) ≥ 2.5 x upper limit of normal (ULN) or ≥ 5.0 x ULN if the transaminase elevation is due to disease involvement
  • known history of Human immunodeficiency virus (HIV)seropositivity
  • hepatitis B virus (HBV) or hepatitis B virus (HCV)active hepatitis

Key Trial Info

Start Date :

July 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 1 2016

Estimated Enrollment :

59 Patients enrolled

Trial Details

Trial ID

NCT01884441

Start Date

July 1 2011

End Date

July 1 2016

Last Update

January 29 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Istituto Clinico Humanitas

Rozzano, MI, Italy, 20089